Legend Biotech (LEGN) Short term Debt (2025 - 2026)
Legend Biotech (LEGN) posted quarterly Short term Debt of $266.0 million for Q1 2026, down 16.64% on a QoQ basis from $319.1 million in Q4 2025.
Legend Biotech (LEGN) Short term Debt (2025 - 2026) Analysis & Trends
Legend Biotech (LEGN) has reported Short term Debt for 2 consecutive years, with $266.0 million the latest figure, recorded in Q1 2026.
- Quarterly Short term Debt changed N/A year-over-year to $266.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.0 million (changed N/A YoY) and the FY2025 annual result came in at $319.1 million, changed N/A from the prior year.
- Short term Debt retreated to $266.0 million in Q1 2026 per LEGN's latest filing, from $319.1 million in the prior quarter.
- Over the last five years, Short term Debt for LEGN reached as high as $319.1 million in Q4 2025 and fell as low as $142.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Legend Biotech | 8.69 Bn | 7.79 Bn | 129.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 266.00 Mn |
| Dec 31, 2025 | 319.10 Mn |
| Sep 30, 2025 | 142.90 Mn |